Where does OCRA's clinical trial data come from?

OCRA indexes clinical trials from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Trials are matched to diseases, investigators, and funded research tracked across the platform.

How do I find clinical trials for ovarian cancer?

Search by condition, treatment type, trial phase, or NCT identifier. Each trial page shows current status, eligibility criteria, study locations, and a direct link to the ClinicalTrials.gov source record.

How often is clinical trial data updated?

Trial data is refreshed through periodic ingestion from the ClinicalTrials.gov v2 API. Status changes, new enrollments, and newly registered trials are captured during each update cycle.

A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)

NCT00628901CompletedPHASE4INTERVENTIONAL

Summary

The purpose of this study is to demonstrate comparability between Contour SE™ Microspheres and Embosphere® Microspheres for achieving post UFE fibroid devascularization in women with symptomatic uterine fibroids.

Key Facts

Lead Sponsor

Boston Scientific Corporation

Enrollment

Start Date

2006-01-01

Completion Date

2009-12-01

Study Type

INTERVENTIONAL

Official Title

A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)

Interventions

Uterine Fibroid Embolization (UFE)Contour SE™ MicrospheresEmbosphere® Microspheres

Conditions

LeiomyomaUterine FibroidsUterine NeoplasmsMenorrhagiaLeiomyomatosis

Eligibility

Age Range

18 Years+

Sex

FEMALE

Inclusion Criteria:

* One or more of the following symptoms: abnormal menstrual bleeding, infertility related to fibroids, pelvic pain, and/or bulk/pressure related symptoms attributed to fibroids: i.e., pelvic pressure, abdominal enlargement, abdominal bloating, gastrointestinal pressure symptoms (backache, constipation), dysfunction of the urinary bladder (urinary frequency, urinary retention), vaginal pressure, and rectal pressure.
* Severity of the symptom(s) warrants invasive treatment
* Willing and able to complete the follow-up requirements outlined in the study design section of the protocol
* Willing to sign a consent form

Exclusion Criteria:

* Active pelvic inflammatory disease or infection
* Any malignancy of the pelvic region
* Endometrial neoplasia or hyperplasia
* Presence of one or more submucosal fibroid(s) with more than 50% growth into the uterine cavity
* Presence of pedunculated serosal fibroid as the dominant fibroid(s)
* Fibroids with significant collateral feeding by vessels other than the uterine arteries
* Presence of arteries supplying the fibroid are not large enough to accept 700-900 micron or 900-1200 micron microspheres
* Coagulopathy
* Atypical anatomy that will not allow for bilateral UFE
* Subject with known severe contrast allergy
* Subjects with known moderate to severe renal disease

Outcome Measures

Primary Outcomes

Number of Participants With Fibroid Devascularization Measured by Contrast Enhanced Magnetic Resonance Imaging (MRI)

MRI uses a large circular magnet and radio waves to generate signals from atoms in the body. These signals are used to construct images of internal structures. Injection of contrast through an IV is done during the test to enhance the view of the uterus. Contrast enhanced MRI was used as a test in this study to verify if blood supply to the fibroids was blocked or interrupted (devascularization).

Time frame: 24-hours post study procedure

Secondary Outcomes

Visual Analog Scale (VAS) Maximum Level of Nausea

Maximum level of nausea was measured using the Visual Analog Scale(VAS). The patient is presented with a picture of a straight line that is 0-10 cm long. The left side of the line (0 cm) represents 'no nausea' and the right side (10cm) of the line represents 'worst nausea imaginable'. The patient is asked to place a mark on the line that represents their level of nausea. For example, a reading of 10cm = worst nausea imaginable.

Time frame: 24 hours after study procedure

Visual Analog Scale (VAS) Maximum Level of Pain

Maximum level of pain was measured using the Visual Analog Scale(VAS). The patient is presented with a picture of a straight line that is 0-10 cm long. The left side of the line (0 cm) represents 'no pain' and the right side (10cm) of the line represents 'worst imaginable'. The patient is asked to place a mark on the line that represents their level of pain. For example, a reading of 10cm = worst imaginable pain.

Time frame: 24 hours after study procedure

Fluoroscopy Time

Fluoroscopy is the method that provides real-time X ray imaging used for guiding a variety of diagnostic and interventional procedures. Fluoroscopy time is described as the amount of time the patient underwent fluoroscopy.

Time frame: During the study procedure (measured in minutes)

Procedure Time

Procedure time is the time in minutes of the first arterial puncture to time of hemostasis (stopping bleeding)

Time frame: During the study procedure (measured in minutes)

Any Adverse Events That the Participant Experienced

Summary of investigator reported adverse events and adverse device effects, including all serious adverse events and unanticipated adverse device effects. Adverse events were collected systematically, meaning they were collected during the participant's follow-up visit, during telephone contacts, or during medical record review.

Time frame: During the hospitalization stay post UFE

Uterine Fibroid Symptom Quality of Life Questionaire (UFS-QOL) Score

The UFS-QoL asks the subjects feelings and experiences regarding the impact of uterine fibroid symptoms and experiences during the previous 3 months. The scores are added and the final total scores range from 0-100. The lowest actual raw score=8, the highest raw score=40, the possible raw score range=32. A formula is then used to transform the value(actual raw score-lowest possible raw score divided by possible raw score range x100). Higher symptom score values are indicative of greater symptom severity or bother and lower scores indicate minimal symptom severity (high scores = bad)

Time frame: Baseline

Uterine Fibroid Symptom Quality of Life Questionaire (UFS-QOL) Score

Time frame: 3-months

Uterine Fibroid Symptom Quality of Life Questionaire (UFS-QOL) Score

The UFS-QoL asks the subjects feelings and experiences regarding the impact of uterine fibroid symptoms and experiences during the previous 3 months. The scores are added and the final total scores range from 0-100.The lowest actual raw score=8, the highest raw score=40, the possible raw score range=32. A formula is then used to transform the value(actual raw score-lowest possible raw score divided by possible raw score range x100). Higher symptom score values are indicative of greater symptom severity or bother and lower scores indicate minimal symptom severity (high scores = bad).

Time frame: 12 months

Health Related Quality of Life (HRQL)Subscores

The HRQL subscales (concern, activities, energy/mood, control, self-conscious, and sexual function were collected from the UFS-QoL. Each individual subscale is added. HRQL Total (sum of 6 subscales); lowest possible raw score = 29, highest possible raw score=145. A formula is used to transform the HRQL raw scores (Highest possible score-actual raw score divided by possible raw score range x 100). Higher scores are indicative of a better HRQL and lower scores indicate a worse HRQL (High=good). The value reported for this measure is the average of all participants scores.

Time frame: Baseline

Health Related Quality of Life Subscores

Time frame: 3 months

Health Related Quality of Life Subscores

Time frame: 12 months

Locations

Hospital of the University of Pennsylvania, Philadelphia, United States

Linked Diseases

Uterine Neoplasms

Uterine Neoplasms — a type of gynecological cancer.